Core Insights - Eli Lilly's tirzepatide is projected to surpass Novo Nordisk's semaglutide in global sales by 2025, claiming the title of "king of drugs" [1] - Eli Lilly reported a total revenue of $65.179 billion for 2025, a 44% year-over-year increase, with a net profit of $20.64 billion, up 95% [1] - Tirzepatide contributed over $36.5 billion in revenue, with sales of the diabetes version reaching $22.965 billion (99% increase) and the weight loss version at $13.542 billion (175% increase) [1] - Novo Nordisk's revenue for 2025 was approximately $48.95 billion, with semaglutide accounting for 73.9% of its revenue, totaling about $36.1 billion [1] Market Dynamics - The pharmaceutical industry is experiencing a shift in leadership, with the "king of drugs" title changing hands more frequently due to patent expirations [2] - Semaglutide's core patent will expire in March 2026, while tirzepatide's patent is expected to last until after 2030, but both are facing increased competition from generics [2] - A price war has begun, with both Eli Lilly and Novo Nordisk announcing price reductions for their key diabetes and weight loss drugs starting November 2025 [2][3] Future Projections - Eli Lilly anticipates total revenue of $80 billion to $83 billion for 2026, representing a 25% increase from 2025 [3] - Novo Nordisk has lowered its 2026 sales guidance, expecting a decline of 5% to 13% due to pricing pressures affecting its diabetes and weight loss drugs [3] - The global obesity treatment market is rapidly evolving, with over 600 drugs in development, primarily in the U.S. and China [3]

Core Insights - The global top-selling drugs for the first half of 2025 have been released, with Novo Nordisk's semaglutide leading the sales at 166.83 billion USD, followed by Merck's pembrolizumab and Eli Lilly's tirzepatide [1][3][4] Group 1: Top-Selling Drugs - Semaglutide from Novo Nordisk achieved sales of 166.83 billion USD, maintaining its position as the "king of drugs" [1][3] - Pembrolizumab from Merck recorded sales of 151.61 billion USD, ranking second [3] - Tirzepatide from Eli Lilly reached sales of 147.34 billion USD, securing the third position [3] Group 2: Sales Growth and Market Dynamics - Semaglutide's sales growth is driven by its three products: Ozempic (95.46 billion USD), Rybelsus (16.79 billion USD), and Wegovy (54.58 billion USD), with Wegovy showing a remarkable growth of 78% [5][6] - Tirzepatide has rapidly gained market share, with Mounjaro's sales skyrocketing from 4.83 billion USD in 2022 to an expected 115.4 billion USD in 2024 [7] - The competition between semaglutide and tirzepatide is intensifying, with both drugs exceeding 140 billion USD in sales for the first half of 2025 [7] Group 3: Market Challenges - The entry of biosimilars has impacted the sales of established drugs, with Janssen's ustekinumab dropping out of the top 10 due to a significant decline in sales [8] - Ustekinumab's sales fell by 38.6% in the first half of 2025, reaching only 32.78 billion USD [8] - Despite challenges, Johnson & Johnson's daratumumab saw a 21.7% increase in sales, reaching 67.76 billion USD, indicating strong demand in the multiple myeloma market [9][10]

Core Insights - The global top-selling drugs for the first half of 2025 have been released, with Novo Nordisk's semaglutide leading the sales at 166.83 billion USD, followed by Merck's pembrolizumab and Eli Lilly's tirzepatide [1][3][4] Sales Performance - Semaglutide achieved sales of 166.83 billion USD, maintaining its position as the top-selling drug [1][3] - Pembrolizumab (K drug) recorded sales of 151.61 billion USD, while tirzepatide reached 147.34 billion USD [3] - Other notable drugs include apixaban at 111.71 billion USD and dupilumab at 80.15 billion USD [3] Market Dynamics - The competition for the title of "King of Drugs" is intensifying, with new entrants like tirzepatide rapidly gaining market share [1][5] - Semaglutide's sales are bolstered by its three product variants, with the weight loss version, Wegovy, showing a remarkable growth of 78% [5][6] - Tirzepatide has been recognized for its rapid market uptake, with sales skyrocketing from 4.83 billion USD in 2022 to an expected 115.4 billion USD in 2024 [7] Product Innovations - Wegovy has recently gained approval for treating metabolic-associated fatty liver disease, which is expected to further enhance its sales [6] - Tirzepatide is the first and only dual-target GLP-1 receptor agonist approved for type 2 diabetes, positioning it as a strong competitor to semaglutide [7] Market Challenges - The entry of biosimilars has impacted the sales of established drugs, with Johnson & Johnson's ustekinumab dropping out of the top 10 due to a significant sales decline [8] - Ustekinumab's sales fell by 38.6% in the first half of 2025, reflecting the challenges faced by original drugs as patents expire [8] Future Outlook - Daratumumab from Johnson & Johnson has shown a 21.7% increase in sales, indicating strong market potential in the multiple myeloma segment [9][10] - The overall trend suggests a shift in market leadership as newer drugs gain traction and established drugs face competitive pressures [1][5][8]